Activation of the Akt-mTOR and MAPK pathways in dedifferentiated liposarcomas
The Akt/mTOR and MAPK pathways play important roles in modulating cellular function in response to extracellular signals, and they are known to be activated in certain kinds of sarcomas. Few investigations have examined these pathways in dedifferentiated liposarcoma (DDLS), in relation to clinicopathological features. Clinicopathological and immunohistochemical analyses were conducted using 99 DDLS specimens. An in vitro study was also conducted to examine the antitumor effects of an mTOR inhibitor and a MEK inhibitor on two DDLS cell lines. The clinicopathological analyses revealed that the AJCC staging was a significant prognostic factor for overall survival and that the tumor size, depth, and location were significant prognostic factors for event-free survival. Phosphorylated Akt (pAkt), pmTOR, pS6RP, p4E-BP1, pMEK, and pERK expressions were positive in 57.4, 52.4, 71.4, 57.1, 84.1, and 50.8 % of the dedifferentiated component of the 63 primary DDLSs. Positive staining for pmTOR was significantly more frequent in the dedifferentiated component than the well-differentiated component. A univariate prognostic analysis revealed that pmTOR expression was associated with poor prognosis in the tumors in the retroperitoneum/ventral body cavity. The mTOR and MEK inhibitors dose-dependently inhibited the cell proliferation of both DDLS cell lines and decreased the expression of downstream pS6RP and pERK, respectively. The combined use of the two inhibitors enhanced antiproliferative activity. In conclusion, the Akt/mTOR and MAPK pathways were activated in DDLS specimens, and the inhibition of these pathways decreased cell proliferation in DDLS cell lines. Our findings suggest that these pathways could be a therapeutic target for patients with DDLS.
KeywordsDedifferentiated liposarcoma Prognosis Mammalian target of rapamycin Mitogen-activated protein kinase Immunohistochemistry
This work was supported by JSPS KAKEN Grant Number 25293088. The English used in this article was revised by KN International (http://www.kninter.com). We would like to express our sincere appreciation to Prof. Masao Tanaka, Department of Surgery and Oncology, Prof. Yoshihiko Maehara, Department of Surgery and Science and Prof. Seiji Naito, Department of urology, Graduate School of Medical Sciences, Kyushu University for kind support for our research.
Compliance with ethical standards
Conflicts of interest
- 1.Dei Tos J. Dedifferentiated liposarcoma. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. WHO classification of tumours of soft tissue and bone. Lyon: International Agency for Research on Cancer (IRAC); 2013. p. 37–8.Google Scholar
- 3.Mertens F, Fletcher CD, Dal Cin P, De Wever I, Mandahl N, Mitelman F, et al. Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study Group. Chromosomes and MorPhology. Genes Chromosom Cancer. 1998;22:16–25.CrossRefPubMedGoogle Scholar
- 12.Dasari A, Messersmith WA. New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. Clin Cancer Res. 2010;16:3811–8.CrossRefPubMedGoogle Scholar
- 25.Pollock RE, Baker LH, Brennan MF, Coombes K, Kattan M, Kneisl JS, et al. Soft tissue sarcoma. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual 7th edn. American Joint Committee on Cancer, Springer: Chicago; 2010. pp 291–298.Google Scholar
- 31.Demetri GD, Chwla SP, Ray-Coquard I, Le Cesne A, Staddon AP, Milhem MM, et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol. 2013;31:2485–92.CrossRefPubMedGoogle Scholar